It proposed that multi-target inhibition, i. e., not only targeting IL-17A/IL-17AR/CR but also inhibiting its co-worker IL17E/IL-17ER, maximizes the clinical efficiency or potency of anti-EGFR such as panitumumab or rrastuzumab for treatments of BC (84, 85). Here, IL17A is linked to breast cancer.